Polylaminin: Brazil's Experimental Spinal Cord Drug Generating Both Hope and Scientific Caution

On September 9, 2025, Brazil's leading nightly newscast aired a story that captivated the country. Bruno Drummond, 31 years old, had been diagnosed with quadriplegia after a car accident in 2018. Following an experimental injection of a compound called polylaminin into his damaged spinal cord, he appeared on national television walking, descending stairs, and dancing for the camera. The researcher behind the treatment, biologist Tatiana Sampaio of the Federal University of Rio de Janeiro (UFRJ), became a national figure almost overnight.

Polylaminin is a laboratory-recreated form of laminin, a protein that is central to neuronal development during the embryonic stage of life. Laminin forms a three-dimensional mesh that guides axonal growth, the extension of nerve fibres that carry electrical impulses between the brain, spinal cord, and the body. After birth, laminin production in the nervous system decreases dramatically. When a spinal cord injury severs the connection between neurons, the absence of this scaffolding protein means axons cannot find a path to reconnect. Sampaio's team, working at UFRJ's Extracellular Matrix Biology Laboratory over more than 25 years, has sought to recreate that scaffolding from proteins extracted from the human placenta and reintroduce it as a polymeric form directly at the injury site.

The scientific record for polylaminin is built on decades of laboratory and animal work. A 2025 study published in Frontiers in Veterinary Science tested the compound in six paraplegic dogs that had not regained mobility despite surgery and months of physiotherapy. Four of the six dogs showed improved balance and were able to take independent steps. No serious adverse effects were observed over six months of monitoring.

The human trial that produced Bruno Drummond's recovery was a small academic pilot study involving eight patients with acute complete spinal cord injuries. Each patient received a single intraspinal injection of polylaminin within 72 hours of the accident. Of the eight participants, two died within the first days from causes the researchers say were related to the severity of their underlying conditions, not to the treatment. Of the six survivors who reached one-month follow-up, Drummond's recovery was the most dramatic. The other five were reported to have regained some degree of voluntary motor control. The study results were published as a preprint on medRxiv in 2024 but have not yet undergone full peer review in a journal.

The Brazilian media response produced both extraordinary hope and significant scientific concern. Within weeks of the September 2025 announcement, patients from across Brazil were seeking access, with some obtaining court orders to receive compassionate use injections. By February 2026, approximately 10 court orders had been granted and more than 30 people had received injections outside of a formal clinical trial structure. Brazilian scientific bodies issued a joint statement in February 2026 emphasising that claims about polylaminin needed to be evaluated through peer review and formal clinical trials.

ANVISA, Brazil's health regulatory agency, has confirmed that there is no current formal request for full regulatory approval pending. A Phase 1 clinical trial to assess safety is scheduled to begin, and Cristalia, the Brazilian pharmaceutical company that acquired polylaminin-related patents in 2022 and 2023, is working toward approval for Phase 2 trials. Sampaio herself has described the current data as preliminary while stating she thinks they strongly suggest some effect.

Polylaminin represents something significant regardless of its clinical outcome: it is an example of Brazilian academic science generating a translational candidate from a public university, developed over decades, that has now achieved commercial partnership, regulatory attention, and unprecedented public visibility.

Sources: Science Magazine AAAS (March 2026) | Frontiers in Veterinary Science (2025) | medRxiv Preprint (2024) | REBEC Clinical Registry | IBIS Brazil Health Innovation Institute | Science Arena